Peptide blend · Research Monograph · Two-compound metabolic blend: Cagri + GLP-1 (5 mg each)

Cagri / GLP-1

Amylin + incretin blend · 10 mg lyophilized

This is a blend. Cagri and GLP-1 are combined in a single 10 mg vial, 5 mg of each. Cagri is a long-acting amylin-analog research compound; GLP-1 is a GLP-1 receptor agonist research compound. The pairing is one of the most studied combinations in the metabolic literature, though the two are characterised separately rather than as a single formulation.

Size
5mg / 5mg
Form
Lyophilized powder blend
View product & pricing → Lot records & COAs

For laboratory research use only - not for human or animal use

Cagri / GLP-1 vial from the Eon Peptides research catalog
Cagri / GLP-1 · 5mg / 5mg · catalog photograph
Available in the Eon catalog - Cagri / GLP-1 from $110.00

Molecular data

Physical formLyophilized powder blend
Available sizes5mg / 5mg

How it works

  1. Cagri

    Amylin Receptor Signalling

    Amylin analogs are characterised at the calcitonin and amylin receptor complexes. Satiety signalling and gastric-emptying rate are the measured endpoints.

    • Amylin receptor complexes
    • Satiety signalling
    • Gastric-emptying rate
  2. GLP-1

    Incretin Receptor Activity

    GLP-1 receptor agonism is characterised for glucose-dependent insulin release, with gastric emptying and food-intake endpoints also measured.

    • GLP-1 receptor engagement
    • Glucose-dependent insulin release
    • Food-intake endpoints
  3. Combined

    Complementary Pathways

    The amylin and incretin arms act through separate receptor systems and are frequently studied in parallel. No interaction data exists for this specific formulation.

    • Separate receptor systems
    • Frequently studied in parallel
    • Interaction not characterised

What the research shows

  1. Metabolic

    Satiety Signalling Models

    Food-intake and satiety endpoints are measured for both arms in preclinical models.

  2. Metabolic

    Glucose Handling

    The incretin arm is studied for glucose-dependent insulin release.

  3. Metabolic

    Energy Balance

    Energy-balance endpoints recur across the amylin and incretin literature.

  4. Methods

    Parallel-Arm Protocols

    One vial supports protocols needing both arms under matched handling.

Specification

ComponentsCagri + GLP-1
Content10 mg per vial (5 mg of each component)
PathwaysAmylin · GLP-1 incretin
FormLyophilized powder blend
Purity≥99% by HPLC
AppearanceWhite to off-white powder
SolubilityWater-soluble
Storage-20°C, protected from light
ClassificationResearch use only

Frequently asked questions

Why combine Cagri and GLP-1?

They act through separate receptor systems and are frequently studied in parallel in the metabolic literature. This vial holds both under matched handling.

Has the combination been characterised as a single formulation?

No. Each compound is characterised separately and no interaction data exists for this specific blend.

How does this differ from Cagri sold on its own?

Cagri 10 mg is the single-compound vial. This blend fixes the ratio at 5 mg Cagri and 5 mg GLP-1.

What purity is documented?

Each lot is analysed by reverse-phase HPLC and released at ≥99%, with a Certificate of Analysis.

How is it stored?

Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles.

  • KLOWFour-peptide blend · 80 mg lyophilized
  • BPC-157 / TB-500Two-peptide blend · 20 mg lyophilized
  • CJC / IPA BlendTwo-peptide blend · GHRH-R and GHS-R pathways
  • GlowThree-peptide blend · dermal and matrix models

For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.